CNS Pharmaceuticals Soars 215% on $22.5 Million Oversubscribed Private Placement

Overview

• CNS Pharmaceuticals, which announced the private placement Monday, jumped about 215% as trading topped 44 million shares against an average near 16,000.
• The company lined up roughly $22.5 million in gross proceeds, a sum that dwarfed its pre-announcement market value of about $1.88 million.
• The financing includes 650,000 common shares at $2.30 and 9,143,479 pre-funded warrants priced at $2.299 with a $0.001 exercise price.
• Pre-funded warrants let buyers pay almost the full cost up front and add almost no cash later, which speeds issuance and can lead to heavy dilution for current holders.
• Healthcare investors ADAR1 Capital, Ikarian Capital, Stonepine Capital, and Nazare Partners participated, with closing targeted for Tuesday as management pursues acquisitions and explores out-licensing of TPI 287 and Berubicin.